Temporal Lobe Epilepsy (TLE) is frequently associated with changes in protein 24 composition and post-translational modifications (PTM) that exacerbate the disorder. O-linked-β-N-25 acetyl glucosamine (O-GlcNAc) is a PTM occurring at serine/threonine residues that integrate 26 energy supply with demand. The enzymes O-GlcNActransferase (OGT) and O-GlcNAcase (OGA) 27 mediate the addition and removal, respectively, of the O-GlcNAc modification. The goal of this 28 study was to determine whether changes in OGT/OGA cycling and disruptions in protein O-29 GlcNAcylation occur in the epileptic hippocampus. We observed reduced global and protein specific 30 O-GlcNAcylation and OGT expression in the kainate rat model of TLE and in human TLE 31 hippocampal tissue. Inhibiting OGA with Thiamet-G elevated protein O-GlcNAcylation, and 32 decreased both seizure duration and epileptic spike events, suggesting that OGA may be a 33 therapeutic target for seizure control. These findings suggest that loss of O-GlcNAc homeostasis in 34 the kainate model and in human TLE can be reversed via targeting of O-GlcNAc related pathways. 35
sucrose, 60 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 28 mM NaHCO3, 0.5 mM CaCl2, 7 mM 139 MgCl2, 5mM glucose, 0.6 mM ascorbate). The cornu ammonis (all CA regions), and the dentate 140 gyrus (DG) region were microdissected and frozen immediately on dry ice. The hippocampus was 141 bisected with the dorsomedial half being divided into four pieces. Using anatomic landmarks, each 142 piece was dissected into CA and DG region. The CA and DG were dissected with a cut along the 143 hippocampal fissure. The tissue was then stored at -80°C for RNA and DNA extraction. 144 2.6 Small Animal Magnetic Resonance Imaging: T1-and T2-weighted images were collected on a 145 9.4T Bruker BioSpin horizontal small bore animal MRI scanner. The imaging parameters were set 146 as follows: 1 mm slice thickness, 1 mm between slice distance, 0.1 x 0.1 x 1 mm voxel size, 30 x 30 147 mm FOV, 27 images per acquisition. T2-weighted hippocampal intensities were normalized to 148 within-slice cortical intensity using ImageJ software (n=5/group). 149 2.7 Western Blotting: Protein concentrations were estimated by Bradford Assay (Biorad), and 25µg 150 of total protein/sample was reduced in 5x sample loading buffer (0.1 M Tris-HCl, 4% SDS, 20% 151 glycerol, 0.2% β-mercaptoethanol, 0.2% bromphenol blue), boiled for 10 min, separated by 10% 152 SDS-PAGE, and transferred onto PVDF membranes using Trans-Blot Turbo transfer system 153 (1704155, BioRad, Hercules, CA, USA). Membranes were activated with methanol for three 154 minutes before transfer, blocked for 1hr at room temperature and incubated overnight at 4°C with 155 primary antibodies following the transfer. Three washes were done with 1x PBST (PBS and 0.01% 156 Tween) between primary and secondary antibodies and after stripping. The membranes were 157 blocked with 1:1 Licor Blocking buffer (P/N 927-40003, Licor) and PBST for one hour at room 158 temperature after transfers and stripping. Imaging was done using Licor Odyssey scanner at 700/800 159 channel, and Licor Odyssey software. Image analysis was done using Image Studio Lite Ver. 3.1.
Sample Preparation for mass spectrometry:
Protein was extracted from rat dorsal hippocampus 161 CA using M-PER (78501, Thermo Fisher Scientific) and quantified using Pierce BCA Protein Assay 162 Kit (23225, Thermo Fisher Scientific). Extracts were diluted in LDS PAGE buffer (NP0007, 163 Invitrogen) followed by reduction, heat denaturing, and separation on an SDS Bis-Tris gel (4-12%, 164 NP0323BOX, Invitrogen). The gels were stained overnight with colloidal blue (89871, Invitrogen). 165
The entire lane comprising each sample was cut into 12 MW fractions and equilibrated in 100 mM 166 ammonium bicarbonate (AmBc). Gel slices were reduced, carboxymethylated, dehydrated, and 167 digested with Trypsin Gold (V5280, Promega, Madison, WI, USA) as per manufacturers' 168 instructions. Following digestion, peptides were extracted, the volume was then be reduced in a 169 SpeedVac to near dryness, and resuspended to 20µl using 95% ddH2O/ 5% ACN/ 0.1% formic acid 170 (FA) prior to analysis by 1D reverse phase LC-ESI-MS2 (as outlined below). 171 2.9 HPLC-electrospray tandem mass spectrometry: Peptide digests were injected onto a 1260 172 Infinity HPLC stack (Agilent, Santa Clara, CA, USA) and separated using a 75 micron I.D. x 15 cm 173 pulled tip C-18 column (00G-4053-E0, Jupiter C-18 300 Å, 5 micron, Phenomenex, Torrance, CA, 174 USA). This system runs in-line with a Thermo Orbitrap Velos Pro hybrid mass spectrometer, 175 equipped with a nano-electrospray source (Thermo Fisher Scientific), and all data was collected in 176 CID mode. The HPLC was configured with binary mobile phases that include solvent A (0.1%FA in 177 ddH2O), and solvent B (0.1%FA in 15% ddH2O / 85% ACN), programmed as follows; 10min @ 178 0%B (2µL/ min, load), 120min @ 0%-40%B (0.5nL/ min, analyze), 15min @ 0%B (2µL/ min, 179 equilibrate). Following each parent ion scan (350-1200m/z @60k resolution), fragmentation data 180 (MS2) was collected on the topmost intense 15 ions. For data dependent scans, charge state 181 screening and dynamic exclusion were enabled with a repeat count of 2, repeat duration of 15.0s, 182 and exclusion duration of 60.0s. 183
Mass Spectrometry Data Conversion and Searches:
The XCalibur RAW files were collected 184 in profile mode, centroided and converted to MXML using ReAdW v. 3.5.1. The mgf files were then 185 created using MzXML2Search (included in TPP v. 3.5) for all scans. The data was searched using 186 SEQUEST, which was set for two maximum missed cleavages, a precursor mass window of 20ppm, 187 trypsin digestion, variable modification C at 57.0293, and M at 15.9949. Searches were performed 188 with a species-specific subset of the UniRef100 database. with 2) T-Test (single tail, unequal variance, cut off p < 0.05), which then were sorted according to 204 the highest statistical relevance in each comparison. For SAM, whereby the weight value (W) is a 205 statistically derived function that approaches significance as the distance between the means (μ1-μ2) 206 for each group increases, and the SD (δ1-δ2) decreases using the formula, W=(μ1-μ2)/( δ1-δ2) [31, 207 32 ]. For protein abundance ratios determined with N-SC's, we set a 1.5-2.0 fold change as the 208 threshold for significance, determined empirically by analyzing the inner-quartile data from the 209 control experiment indicated above using ln-ln plots, where Pierson's correlation coefficient (R) was 210 0.98, and >99% of the normalized intensities fell between +/-1.5 fold. In each case, any two of the 211 three tests (SAM, Ttest, or fold change) had to pass. 212
Gene ontology assignments and pathway analysis were carried out using MetaCore (GeneGO 213 Inc., St. Joseph, MI, USA). In addition, the final proteins list is analyzed using the auto-expand 214 algorithm within MetaCore using the default setting (i.e. expanded by 50 nodes). In parallel, the 215 expand-by-one algorithm is used to identify connections to the neighboring proteins, known drug 216 interactions, and any known correlation to a disease, or specific biological process. Interactions 217 identified within MetaCore are manually correlated using full-text articles. Detailed algorithms have 218 been described previously [33, 34] . 219
Human Electrophysiology:
The electrophysiological data obtained from slice studies were 220 derived from patients with medically intractable epilepsy undergoing elective neurosurgical tissue 221 resection for the removal of a sclerotic hippocampus. All patients gave their informed consent, 222 before surgery, for the use of the resected brain tissue for scientific studies. This study was approved 223 by the Newcastle and the North Tyneside 2 Local Research Ethics Committee (06/Q1003/51) (date 224 of review 03/07/06) and had clinical governance approved by the Newcastle Upon Tyne Hospitals 225 NHS Trust (CM/PB/3707). 226
In vitro human neocortex recordings:
Briefly, human cortical samples were derived from 227 material removed as part of the surgical treatment of medically intractable cortical epilepsy from the 228 mesial temporal lobe regions with the written informed consent of the patients. Slices were prepared 229 from these samples using methods as previously described [35] [36] [37] . The time between resection and 230 slice preparation was <5 min. Extracellular recordings (DC-500 Hz) were conducted with ACSF-231 filled glass microelectrodes (2 MΩ) connected to an extracellular amplifier (EXT-10-2F, npi 232 electronic GmbH, Tamm, Germany). Signals were digitized (5 kHz) and recorded on a computer and 233 then extracellular field recordings were analyzed to detect events using a custom-written code in 234 Matlab2015b (Mathworks, MA, USA). 
Global protein O-GlcNAcylation changes in epileptic rats. 279
Next, we sought to investigate specific proteins that displayed differential O-GlcNAcylation 280 expression associated with TLE pathology. Using HPLC-electrospray tandem mass spectrometry we 281 measured the abundance of proteins that had significantly altered O-GlcNAcylation in the CA 282 regions of the hippocampus at 8 weeks post-SE. We found that 59 proteins were significantly 283 differentially expressed in TLE, with seventeen of these 59 proteins exhibiting changes in O-284 GlcNAc marks. Gene ontology analysis revealed that the majority of diseases associated with 285 differential expression of these proteins were neurodegenerative or cytoskeletal in nature. 286
Additionally, among these seventeen proteins, twelve had been reported to be associated with 287 epilepsy in the literature[3] (Table1) (Fig 2a) . 288
In addition to measuring O-GlcNAcylation, we also measured phosphorylation and 289 discovered increases in protein phosphorylation, particularly on those proteins that had shown 290 decreases in protein O-GlcNAcylation. We next analyzed overall protein expression against protein 291 phosphorylation and protein O-GlcNAcylation (Supplemental Fig.2a-b ) revealing two distinct 292 cluster groups. These clusters indicated that increased protein expression was positively correlated 293 with increased protein phosphorylation, and only a few of the more highly expressed proteins also 294 had changes in O-GlcNAcylation. In contrast to phosphorylation, increased protein O-295
GlcNAcylation was predominantly seen in proteins with decreased in expression. These clusters 296 persisted when O-GlcNAcylation and phosphorylation were plotted against each other 297 (Supplemental Fig.2c ). The Z-scores were plotted from each biological replicate against either 298 modification to demonstrate the contrast between their fold change (Supplemental Fig.2d-e ). Taken 299 together our mass spectrometry analysis corroborated our findings that overall protein O-300
GlcNAcylation was decreased in the epileptic animal hippocampus while highlighting the particular 301 proteomic ontologies affected by this loss. Additionally, our findings revealed that certain proteins 302 actually show increased O-GlcNAcylation in the epileptic hippocampus. Collectively, these findings 303 provide evidence that differentially expressed proteins and changes in PTMs are associated with 304 TLE and other disease states highlighting the importance of protein PTM in homeostasis. 305
OGA inhibition in the epileptic hippocampus via acute Thiamet-G treatment reduces 306 epileptiform activity. 307
The observed global loss of O-GlcNAcylation and OGT prompted additional experiments to 308 determine the role of this PTM in epilepsy. Using the KA model of epilepsy, we recorded cortical 309 brain activity and seizures with EEG one month post-SE. We then administered Thiamet-G 310 (10mg/kg/day), a known OGA inhibitor used to increase O-GlcNAcylation, once a day for three 311 consecutive days in order to measure its effect on epileptiform brain activity (Fig 3a) . We measured 312 baseline EEG activity between control animals and epileptic animals and found that epileptic 313 animals demonstrating higher power than the controls indicating more epileptiform activity (Fig 3b-314 c). The epileptic rats presented with sharp spikes and larger amplitudes than the control animals that 315 depicted synchronous activity or seizures in the spectrogram with warmer colors. These epileptic 316 animals then underwent a daily regimen of OGA inhibition for three days while having their brain 317 activity measured (Fig 3-d) . Following three days of Thiamet-G treatment, epileptic rats displayed a 318 reduction in epileptic waveform and a decrease in the number of seizures experience per day and 319 seizure duration (t(7)=1.999,p=0.858, t(34)=3.497, p=0.0013; Fig. 3e-f ). We then unraveled the 320 spectrogram using a power spectrum in order to measure the significant changes in power between 321 frequencies for each day of Thiamet-G treatment. (Fig. 3g) . The frequencies were divided into bands 322 of brainwaves that are characterized by their range in frequency and behavioral characteristics. For 323 instance, lower band frequencies such as delta and theta waves are associated with sleep, while 324 higher frequency bands such as gamma are more closely associated with consciousness and 325 attentiveness [39] . These bands can be used to characterize seizure severity. In this study, OGA 326 inhibition helped restore the power of the lower frequencies (delta-alpha) more so than the higher 327 frequencies (beta-gamma) to the baseline of the control group. 328
We furthered analyzed each frequency type against their relative power. As expected the 329 largest powers for each given frequency band were from the epileptic rat recordings prior to 330 treatment (t(32-52)=, p=0.0016-<0. 0001; Fig 3h) . By the first day of treatment, these bands showed a 331 reduction in power and began to mirror the power levels of the non-epileptic rats, with the exception 332 of the gamma frequency. This discrepancy between the gamma frequency and the trend from the 333 other bands could be explained by a local measure of activity and not by an overall global cortical 334 network due to a single measurement of activity with an electrode. With each day of treatment, the 335 relative power of each band decreased with the exception of the theta band which plateaued 336 immediately after the first treatment of Thiamet-G. This band is typically characterized by the 337 excitatory regular spiking, and intrinsic bursting pyramidal neurons, suggesting that inhibition of 338 OGA via Thiamet-G may preferentially target this group of neurons more readily. 339
Chronic inhibition of OGA activity in epileptic rats increases hippocampal atrophy 340
Although OGA inhibition dampened epileptiform activity and seizure duration in a wide 341 spectrum of frequencies, we sought to determine if there were any morphological changes associated 342 with the Thiamet-G treatment over a prolonged period of usage. Hippocampal scarring and/or gliosis 343 is often observed in animal models of TLE as well as in humans, where it leads to hippocampal 344 atrophy. Hippocampal atrophy in TLE patients is observed using MRI T2 weighted scans where the 345 ventricles adjacent to the hippocampus expand due to a reduction of size in the hippocampus. We 346 created epileptic rats as previously described, and scanned these animals in an MRI machine at eight 347 weeks post-injection in order to record their ventricular volumes prior to treatment. We then began a 348 two-week treatment regimen for these animals with either saline or Thiamet-G (10mg/kg/day) and 349 measured their ventricular volumes after treatment (Fig 4a) . Coronal T2 pre/post scans were taken of 350 saline and Thiamet-G injected rodents (Fig.4b ). Voxels were quantified and compared to non- Following MRI scans, animals were sacrificed and brain tissue was processed for 358 immunohistochemistry experiments. We stained brain slices for GFAP as a marker for gliosis 359 Specifically, we wanted to ask whether OGA's expression was altered in epilepsy, and if so, whether 373
Thiamet-G treatment restored OGA expression to homeostatic levels. We first looked at OGA 374 protein expression in our epileptic animals that were treated for two weeks with Thiamet-G, (One 375 way ANOVA F=1.852 p=0.085 Fig. 5a-b) . We noticed no significant changes in OGA protein 376 expression in control animals treated with Thiamet-G. Although not significant, we did notice a 377 trend in increased OGA protein expression in epileptic animals. When these animals were treated 378 with Thiamet-G, levels of OGA expression resembled those of saline-treated controls. 379
Based on our proteomic analysis ( Fig.2a) , we identified Sortilin-Related Receptor (SORL1) 380 and tropomodulin 2 (Tmod2) as proteins that undergo increased and decreased protein O-381 GlcNAcylation in TLE, respectively (Supplemental Fig.4) . SORL1 is a receptor that binds to LDL 382 and transports it into the cells via endocytosis, a process that is subject to inhibition upon binding to 383 the receptor-associated protein (RAP) [44] . SORL1 has also been implicated in APP trafficking to 384 and from the Golgi apparatus and in Alzheimer's disease [45, 46] . Tmod2 is an actin-binding protein 385 that stabilizes ADP-bound actin monomers onto actin filaments and is downregulated in epilepsy 386 [47, 48] . To test the effect of Thiamet-G administration on these proteins' PTMs we used 387 immunoprecipitation followed by Western blot to interrogate the levels of O-GlcNAcylaion on these 388 proteins specifically. We observed no differences in O-GlcNAcylation om immunoprecipitated 389 SORL1, nor did we find any differences in association with OGT (Fig 5c) . Immunoprecipitation of 390 Tmod2 revealed slight increases in O-GlcNAcylation in animals treated with Thiamet-G, along with 391 decreases of total O-GlcNAcylation in the inputs, or the raw unimmunoprecipitated samples (Fig  392   5d ). Furthermore, no differences were observed in the degree of association between Tmod2 and 393 OGT. These results suggest that Thiamet-G cannot restore the decreased levels of O-GlcNAcylation 394 of SORL1 and Tmod2 specifically in epileptic rats, a finding which led us to ask whether these 395 observations are similar in human, resected TLE samples and whether Thiamet-G might have a 396 greater impact on human O-GlcNAcylation than it did on rats. 397 
Deficits in O-GlcNAcylation and OGT in patients with TLE 399
Our initial rodent studies have shown that O-GlcNAcylation and OGT are downregulated in 400 the hippocampi of epileptic rats, but we were unsure of how O-GlcNAcylation and OGT might 401 behave in human TLE tissue. We began by measuring O-GlcNAcylation and OGT expression in 402 resected human hippocampus from TLE patients and compared them to age-matched controls from 403 post-mortem human hippocampus tissue (Fig. 6a) . We observed a significant loss of O-404 Tmod2 were being modified in the same manner as we had seen in our epileptic rats. We 408 immunoprecipitated SORL1 and Tmod2 and, in the rats, we observed no differences in O-409
GlcNAcylation of the proteins, nor any differences in their interaction with OGT (Fig 6d) .
OGA inhibition in human TLE resected tissue decreases spike events and increases O-411

GlcNAcylation. 412
Seeing as human TLE patient samples exhibited decreases in O-GlcNAcylation, we then 413 wanted to know if restoring O-GlcNAcylation with Thiamet-G would decrease seizure spike events 414 as observed in the rats treated with Thiamet-G. To test this hypothesis we obtained samples from 415 TLE patients undergoing surgical resection. We immediately placed these samples in oxygenated 416 ACSF, sectioned the tissue, and allowed them to acclimate to the bath for 1hr (Fig 7a) . Following a 417 1hr incubation at room temperature, we recorded baseline activity for 1hr, finding that each slice 418 exhibited spontaneous interictal-like activity. After 1 hr, slices were bathed in Thiamet-G (100 µM) 419 for 3 hrs and the samples frozen for later molecular processing. 420
Prior to treatment with Thiamet-G, these slices exhibited an average of 66 spikes per minute, 421 a rate which decreased to an average of 40 spikes per minute after one hour of treatment in Thiamet-422 G solution (Fig7b-d) . Importantly, slices that were not treated with Thiamet-G showed no change in 423 average spikes per minute over time. In this way, we showed that bath application of Thiamet-G to 424 hyper-excitable human hippocampus significantly decreased spike frequency, recapitulating the 425 similar effect that we observed in vivo in our epileptic rats. 426
We next examined the O-GlcNAcylation, OGT, and OGA levels in these tissues (Fig 7e) . 427
Protein O-GlcNAcylation generally increased with Thiamet-G treatment and decreased with vehicle 428 control treatment depending on whether the tissue had electrophysiological recordings performed. 429 (Fig 7f) . OGT levels increased with recording and Thiamet-G treatment but not with Thiamet-G 430 treatment alone; OGA, which is enzymatically inhibited by Thimaet-G increased during our 431 electrophysiology recordings but showed little change with Thiamet-G treatment alone. Overall, we 432 find that O-GlcNAcylation and OGT levels are decreased in epilepsy, but promoting this PTM 433 pharmacologically resulted in decreased seizure frequency and, spikes, as well as increased protein 434 O-GlcNAcylation. 435
Discussion 436
The current study demonstrates that O-GlcNAcylation and OGT are decreased in the 437 CA1/CA3 regions of the hippocampus in a rodent model of epilepsy. By pharmacologically targeting 438 this modification through pharmacological inhibition of OGA, we were able to raise global protein 439 O-GlcNAcylation levels, not only in epileptic rats but in resected human hippocampus tissue as well. 440
To our knowledge, this is the first demonstration of a role for protein O-GlcNAcylation and its 441 mediators in epilepsy. This is further supported by prior studies suggesting that this PTM is involved 442 in prolonged seizure activity [3, 4] . Additionally, we demonstrated that the loss of OGT and O-GlcNAcylation does not present a 449 homogeneous expression profile. We showed that although the majority of proteins showed 450 decreased O-GlcNAcyaltion levels, there were some proteins that showed an increased in this PTM. 451
Moreover, we demonstrated that proteins that have been associated with epilepsy had differentially 452 expressed O-GlcNAc levels, changes that potentially alter their structure and function in TLE. 453
Finally, we identified a novel biological target, OGA, which can be successfully depressed by 454
Thiamet-G to promote O-GlcNAcylation levels and decrease the number of seizures and spikes in 455 vivo both in rats and in human tissue. Although chronic inhibition of OGA in epileptic rats did not prevent or reverse ventricular expansion we did find that Thiamet-G treatment in epileptic animals 457 and humans tissue could be used to reduce seizures and spike frequency. In future studies, it may be 458 of interest to treat these rodents with Thiamet-G during earlier stages of epilepsy pathogenesis, 459 during the onset of status epilepticus to investigate whether Thiamet-G can delay or halt 460 epileptogenesis as a preventative treatment. 461
In summary, our results suggest that protein O-GlcNAcylation and its mediators play a 462 previously unknown role in TLE and its animal models (Fig 8) . Experimental outlined. Samples were taken from patients that had gone temporal lobectomy that 542 were unresponsive to AED. Samples were immediately placed in oxygenated ACSF and allowed to 543 acclimate for 1hr. Baseline recording of activity was taken for 1hr followed by bath application of 544 Thiamet-G. Samples were flash frozen and stored at -80°C. 
